(Adnkronos) - “Il linfoma diffuso a grandi cellule B è il tipo più comune di linfoma non-Hodgkin. È generalmente considerato un linfoma aggressivo. Senza trattamento, la prognosi per i pazienti è generalmente sfavorevole. Negli Stati Uniti, si registrano circa 20.000-25.000 casi ogni anno. In Italia, si contano circa 4.000-5.000 nuovi casi. La malattia è curabile nella grande maggioranza dei pazienti. Dal punto di vista epidemiologico, è leggermente più comune nei maschi. L'incidenza della malattia aumenta con l'età. Pertanto, l'età media alla diagnosi è generalmente verso la fine della sesta decade della vita. Questa malattia è più comune nei pazienti di origine europea, quindi più frequente nei bianchi”, ha spiegato Mehdi H. Hamadani, Director, BMT & Cellular Therapy Program at Medical College of Wisconsin
Category
🗞
NewsTranscript
00:00So, diffused large B cell lymphoma is the most common type of non-Hodgkin lymphomas.
00:11It is generally considered an aggressive lymphoma, which generally means that the lymphoma cells
00:18are fast growing.
00:20Patients generally present with symptoms.
00:25If you don't treat the disease, patients generally have poor outcomes.
00:33Diffused large B cell lymphoma being the most common non-Hodgkin lymphoma in the United
00:38States, there are about 20,000 to 25,000 cases of diffused large B cell lymphoma every year.
00:46In Italy, there are about 4,000 to 5,000 new cases of diffused large B cell lymphoma.
00:54The disease is aggressive, but it is also curable in vast majority of patients.
01:01In terms of the epidemiology of the disease, it is slightly more common in males.
01:08The incidence of the disease goes up as we get older, so average age at the time of diagnosis
01:15is generally late in the sixth decade of life.
01:20This disease is more common in patients with European ancestry, so more common in whites,
01:27slightly less common in African Americans or black patients.
01:32The incidence of the disease is slightly higher in western hemisphere, and as you go to the
01:38eastern part of the world, the incidence of the disease becomes a little less common.
01:44Now diffused large B cell lymphoma, when it presents, majority of patients have advanced
01:49stage disease, and the disease generally can involve any organ of the body, but the
01:55most common presentation is in lymph nodes.
01:59Diffused large B cell lymphoma, like most blood cancers or hematological malignancy,
02:07is an uncommon disease.
02:10The global incidence is generally under five cases per million patient population, and
02:18the disease is generally more common in individuals at advanced stage, so median time of diagnosis
02:26or median age of diagnosis, for example in the United States, is the late sixth decade
02:33of life, or 67 years.
02:36So diffused large B cell lymphoma treatments have been improving over the years, with modern
02:44chemoimmunotherapy drugs in patients with advanced stage disease, meaning stage three
02:50or four disease, we expect now that approximately 65 to 70% of patients are cured with first
03:00line treatments, among patients with early stage disease, meaning stage one or two disease,
03:07the cure rates are even better, in the range of mid 70% to 80%.
03:14Unfortunately, despite the advances, approximately 20 to 35% of patients, depending on their
03:22characteristic and stage of diagnosis, will relapse after receiving front line therapies.